The invention relates to selective partial adenosine A1 receptor agonists of formula (I) and to the use thereof for the treatment and/or prevention of diseases and to the use thereof for producing medicaments for treating and/or preventing diseases, preferably acute and/or chronic renal diseases (primary disease and secondary disease) with or without accompanying acute and/or heart diseases.